The 340B Drug Discount Program was created in 1992 and requires pharmaceutical manufacturers participating in Medicaid to sell drugs to “Covered Entities” (CEs), including non-profit hospitals like the Cleveland Clinic, at discounts of 20 to 50 percent. The program grew from $9 billion in 2014 to $66 billion in 2023, making it the second-largest federal […]
The federal 340B Drug Pricing Program was intended to provide discounts on drugs to patients but the lack of a clear intent and patient definition, along with inadequate oversight, has led to the program being exploited by hospitals and contract pharmacies to generate millions of dollars in profit. The discounts are supposed to be provided […]
Prices controls have always disrupted the marketplace and created shortages or excesses.
Price controls will result in the loss of life due to a lack of future research and development.
Price controls on pharmaceuticals will not lower prices and will lead to fewer future cures.
The price controls found in the BBBA leave patients worse off.
The BBBA is more big government socialism, with a price tag of $4.9 trillion over 10 years.
The Build Back Better Act will cost lives by devastating the development of future cures.
The Supreme Court tossed out ObamaCare lawsuit, California et al v. Texas, stating the plaintiffs have no standing.
The U.S. public health system has a trust problem due to their handling of COVID-19.
